ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,672,238 | -7.0% | 231,988 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $5,024,860 | -46.1% | 231,988 | -30.1% | 0.00% | -50.0% |
| Q2 2022 | $9,330,436 | +113.4% | 332,044 | +250.4% | 0.00% | +100.0% |
| Q1 2022 | $4,371,765 | -3.3% | 94,750 | +76.2% | 0.00% | 0.0% |
| Q4 2021 | $4,521,000 | +26.1% | 53,783 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $3,584,000 | +68.8% | 53,783 | +34.8% | 0.00% | – |
| Q2 2021 | $2,123,000 | +69.2% | 39,906 | +38.0% | 0.00% | – |
| Q1 2021 | $1,255,000 | +145.6% | 28,926 | +193.8% | 0.00% | – |
| Q4 2020 | $511,000 | – | 9,844 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |